Evidence Table 96. KQ 3—Continuous Anemia: Other parameter (e.g. ferritin, MCV, MCH). Specify outcome—Hemoglobin

| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **CVD**  **Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome/ Unit of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Additional Comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Macan 200640  Parallel | Unclear | Warfarin | NR | Garlic | 22 | NR  Unit: g/dl | NR | Mean:-0.2  SD:0.6 | NR | p-value for comparison of changes of mean from baseline between two groups: 0.210 | Medium |
| Placebo | 26 | NR | Mean:0.0  SD:0.8 |
| Napoli 199852  Parallel | Unclear | Pravastatin | 20-40 | Vitamin E |  | NR  Unit: NR | NR | NR | NR | No differences in routine laboratory tests or adverse events were registered during the study. In particular there were no differences between the values recorded in each individual after treatment compared to baseline values, and no differences between the treatment groups.” | Medium |
| No Treatment |  | NR | NR |

Evidence Table 96. KQ 3—Continuous Anemia: Other parameter (e.g. ferritin, MCV, MCH). Specify outcome—Hemoglobin (continued)

| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **CVD**  **Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome/ Unit of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Additional Comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lee 200836  Parallel | At high risk for CHD | Warfarin | 3.5 | Ginseng | 12 | NR  Unit: g/dl | Mean: 13.1  SD: 1.03 | Mean: -0.25 | NR | There were no statistically significant differences between the ginseng group and control group. | N/A |
| No Treatment | 13 | Mean:14.05  SD: 1.41 | Mean:-0.26 |
| Wolf 200868  Crossover | Mixed:  Low and/or Moderate | ASA | 500 | Gingko biloba |  | NR  Unit: NR | NR | NR | NR | Study states that: Laboratory findings in all subjects were un-remarkable and did not indicate any differences between the treatment groups. | Low-medium |
|  |  | NR | NR |
| Hansen 199329  Crossover | Mixed:  Low and/or Moderate | Lovastatin | 40 | Omega-3 | 14 | NR  Unit: % change | NR | % Mean: 0  SD: 1  P: NS | NR | N/A | Medium |
| No treatment | 14 | NR | % Mean: 0  SD: 1  P: NS |